Safety of Trazodone and Clonazepam in Pregnancy
Neither trazodone nor clonazepam are contraindicated in pregnancy, but both require careful risk-benefit assessment, with trazodone having more reassuring safety data than clonazepam.
Trazodone in Pregnancy
Trazodone can be used during pregnancy when clinically indicated, as available evidence does not demonstrate increased risk of major malformations. The FDA drug label states that published prospective cohort studies, case series, and case reports over several decades have not identified drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes 1.
Evidence Supporting Trazodone Use:
- The largest comparative study (221 trazodone-exposed pregnancies) found no significant increase in major congenital anomalies (0.6% vs 2.6% in SSRI-exposed controls) 2
- A systematic review of 14 studies found no consistent evidence linking trazodone to increased risks of congenital malformations, stillbirths, or low birth weight 3
- A multicentre prospective study (147 pregnancies) showed major malformation rate of 1.6%, within the baseline population rate of 1-3% 4
Important Caveats:
- Some studies suggest possible association with spontaneous and therapeutic abortions, though data are limited 3
- Animal studies showed fetal resorption and congenital anomalies at 7.3-22 times the maximum recommended human dose 1
- Untreated depression itself carries significant maternal and fetal risks that must be weighed against medication risks 1
Clonazepam in Pregnancy
Clonazepam requires more caution than trazodone, as it is a benzodiazepine with known class-related concerns, though available data do not definitively establish teratogenicity.
Evidence on Clonazepam:
- The FDA label warns that studies in pregnant animals have shown harmful effects of benzodiazepines on the developing fetus 5
- Neonates may experience breathing problems, feeding problems, hypothermia, and withdrawal symptoms when mothers use benzodiazepines late in pregnancy 5
- A surveillance study of 52 clonazepam-exposed infants (43 monotherapy) found one infant (3.0%) with dysmorphic features, growth retardation, and tetralogy of Fallot, but this did not represent a statistically significant increase 6
- A case series of 38 women using clonazepam during pregnancy showed no orofacial anomalies, neonatal apnea, or withdrawal syndromes, though two infants had transient distress when clonazepam was combined with imipramine 7
Critical Warnings for Clonazepam:
- Do not stop abruptly - sudden discontinuation can cause status epilepticus (seizures that will not stop) 5
- Infants require close observation for drowsiness, hypotonia, respiratory distress, and withdrawal symptoms
- Clonazepam passes into breast milk and is detectable in infant serum 5
Clinical Decision Algorithm
For Depression/Anxiety/Insomnia in Pregnancy:
- First-line approach: Consider trazodone over clonazepam given more reassuring safety profile
- If possible, avoid all medications in first trimester when organogenesis occurs and malformation risk is highest
- If medication necessary in first trimester: Trazodone preferred; use lowest effective dose
- For clonazepam: Reserve for situations where benefits clearly outweigh risks (e.g., severe panic disorder, seizure control)
- Never discontinue clonazepam abruptly - taper gradually under medical supervision to prevent maternal seizures
Monitoring Requirements:
- Enroll in pregnancy exposure registry (National Pregnancy Registry for Antidepressants: 1-844-405-6185) 1
- For clonazepam: Plan for neonatal observation unit availability at delivery
- Monitor neonate for poor adaptation syndrome, respiratory depression, hypotonia, and withdrawal symptoms
The fundamental principle: Untreated maternal psychiatric illness carries its own substantial risks to both mother and fetus, including poor prenatal care, substance use, suicide, and adverse pregnancy outcomes. These risks must be balanced against medication risks in shared decision-making with the patient 1, 5.